U.S. Markets
Trump administration indefinitely delayed BALANCE, a Medicare pilot to expand GLP-1 weight-loss drug coverage through private insurers, Axios reports
News detail
Medicare will instead cover the drugs through a transitional programme from July until the end of 2027 UnitedHealth (UNH), Eli Lilly (LLY), Novo Nordisk (NOVOB DC) and AHIP were cited around insurer concerns, beneficiary access and next steps
Related stocks
3 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
